Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €57.62 EUR
Change Today +0.478 / 0.84%
Volume 2.3K
As of 8:54 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2 Kingdom Street

London, W2 6BD

United Kingdom

Phone: 44 20 7604 8000

Fax: 44 20 7604 8151

e and Gastrointestinal In 2014, the company progressed various assets in development, obtained approval for Movantik/Moventig in the U.S. and EU, and entered into an alliance with Eli Lilly and Company (Lilly) for its beta secretase clearing enzyme inhibitor, AZD3293, as a potential treatment for Alzheimer’s disease. Infection Marketed Products Synagis1 (palivizumab) is a humanised monoclonal antibody used to prevent serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients at high risk of acquiring respiratory syncytial virus disease. Cubicin2 (daptomycin) is a cyclic lipopeptide anti-bacterial used to treat serious infections in hospitalised patients. Merrem/Meronem3 (meropenem) is a carbapenem anti-bacterial used to treat serious infections in hospitalised patients. Zinforo4 (ceftaroline fosamil) is a novel injectable cephalosporin used in community-acquired pneumonia and complicated skin and soft tissue infections. FluMist/Fluenz (influenza vaccine live, intra-nasal) is an intra-nasal, live, attenuated, and trivalent influenza vaccine. FluMist Quadrivalent/Fluenz Tetra (influenza vaccine live, intra-nasal) is an intra-nasal, live, attenuated, and quadrivalent influenza vaccine. The company has a portfolio of medicines for serious Gram-positive and Gram-negative bacterial infections, and is working to develop additional medicines to fight these infections. In addition to CAZ AVI, the company is developing other antibacterial compounds, including Aztreonam avibactam (ATM AVI), MEDI4893, and MEDI3902. Aztreonam avibactam (ATM AVI) is a Phase I compound being developed jointly with Forest to target Gram-negative bacteria with a metallo-beta-lactamase resistance mechanism. This bacteria is endemic in India and spreading worldwide. MEDI4893 is a Phase II compound that received fast track designation from the US Food and Drug Administration (FDA) in 2014. MEDI4893 is an antibody directed against Staphylococcus aureus, a major cause of negative clinical and activity outcomes in hospitals. MEDI3902 is a Phase I compound that received fast track designation from the FDA in 2014. MEDI39002 is an antibody directed against Pseudomonas aeruginosa, a dangerous and resistant Gram-negative bacterium. Neuroscience Marketed Products Seroquel IR (an immediate release formulation of quetiapine fumarate) is an atypical anti-psychotic generally approved for the treatment of schizophrenia and bipolar disorder (mania, depression and maintenance). Seroquel XR (an extended release formulation of quetiapine fumarate) is generally approved for the treatment of schizophrenia, bipolar disorder, major depressive disorder and, on a more limited basis, for generalised anxiety disorder. Diprivan (propofol) is an intravenous general anaesthetic used to induce and maintain general anaesthesia, intensive care sedation and conscious sedation for surgical and diagnostic procedures. EMLA (lidocaine and prilocaine) is a local anaesthetic for topical application (cream and patch) to prevent pain associated with injections and minor surgical procedures, and to facilitate cleansing/debridement of leg ulcers. Naropin (ropivacaine) is a long-acting local anaesthetic for surgical anaesthesia and acute pain management. Vimovo1 (naproxen/esomeprazole magnesium) is generally approved for symptomatic relief in the treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis in patients at risk of developing non-steroidal anti-inflammatory drug-associated gastric and/or duodenal ulcers. Xylocaine (lidocaine) is a short-acting local anaesthetic for topical and regional anaesthesia. Zomig (zolmitriptan) is used for the acute treatment of migraine, plus for the acute treatment of cluster headache in the EU. Zomig is available in three formulations: oral tablet; orally dispersible tablet; and nasal spray. In Neuroscience, the company focuses on developing new medicines, primarily for Alzheimer’s and Parkinson’s diseases and pain control. In 2014, the company entered into an important agreement with Lilly to jointly develop and commercialise a

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEG:GR €57.62 EUR +0.478

ZEG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.46 USD +0.45
BASF SE €79.89 EUR +0.26
Celgene Corp $115.15 USD +0.235
Eli Lilly & Co $84.18 USD +0.40
Valeant Pharmaceuticals International Inc C$274.66 CAD +1.80
View Industry Companies
 

Industry Analysis

ZEG

Industry Average

Valuation ZEG Industry Range
Price/Earnings 65.3x
Price/Sales 3.2x
Price/Book 4.9x
Price/Cash Flow 65.3x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.